Purpose: To demonstrate the feasibility of preoperative Hyperfractionated Accelerated RadioTherapy (preop-HART) in rectal cancer and to explain the rationales to switch from postoperative HART to preoperative HART. Methods and 1989. In trial Materials: Fifty-two consecutive patients were introduced in successive Phase I trials since 89-01. m&operative HART (48 Gv in 3 weeks) was applied in 20 patients. In nine patients with locally advanced rectal cancer, considered unresectable by the surgeon, 32 Gy in 2 weeks was-applied prior to surgery (trial 89-02). Since 1991, 41.6 Gy in 2.5 weeks has been applied preoperatively to 23 patients with T3-T4 any N rectal cancer immediately followed by surgery (trial 91-01). All patients were irradiated at the department of radiation-oncology with a four-field box technique (1.6 Gy twice a day and with at least a 6-h interval between fractions). The minimal accelerating potential was 6 MV. Acute toxicity was scored according to the World Health Organization (WHO for skin and small bowel) and the Radiation Therapy Oncology Group criteria (RTOG for bladder). This was done weekly during treatment and every 3 months thereafter. Small bowel volume was estimated by a modiiied "Gallagher's" method. Results: Acute toxicity was acceptable both in postoperative and preoperative setup. The mean acute toxicity ~significantly lower in trial 91-01 compared to 89-01. This difference was due to the smaller amount of small bowel in irradiation field and lower total dose in trial 91-01. Moreover, there was a significantly reduced delay between surgery and radiotherapy favoring trial 91-01 (median delay 4 days compared to 46 days in trial 89-01). Nearly all patients in trial 89-02 and 91-01 underwent surgery (31 out of 32; 97%). Resection margins were negative in 29 out of 32. Hospitalization duration in trial 91-01 was not significantly different from trial 89-01 (19 vs. 21 days, respectively). Conclusions: Hyperfractionated accelerated radiotherapy immediately followed by surgery is feasible as far as acute toxicity is concerned. Preoperative HART is favored by a significantly lower acute toxicity related, in part, to a smaller amount of irradiated small bowel, and a shorter duration of the delay between radiotherapy and surgery. Moreover, the hospital stay after preoperative HART is not significantly increased.
INTRODUCTION
The mainstay of treatment in rectal cancer is surgery (16, 33, 38) . The actuarial risk of local recurrence rate after surgery alone is high especially for infiltrative rectal cancer (UICC T3-T4) and positive lymph node involvement (29, 38, 43) . Radiation therapy has been proposed as an adjuvant treatment modality both in pre-or postoperative setup (11, 44, 45) . In 1989, we ran a Phase I trial aimed at introducing a hyperfractionated accelerated schedule in a postoperative setup (trial 89-01) (8). The rationale to accelerate was based on the rapid occurrence of local recurrence after surgery. Moreover, as stated by Cox ef al., there is a continuous need to study "fractionation in radiotherapy as an important modality to be pursued in clinical studies." Those fractionation studies serve as "the background for the investigation of adjuncts such as chemical modifiers, hyperthermia, as well as integrated treatment with cytotoxic chemotherapy and/or surgical resection" (9). The hypothesis of rapid proliferation of rectal cancer cells at the origin of recurrence has been confirmed recently by in vivo assessment of potential doubling time (T,,) (3, 36, 48, 54) . Radiobiological models predict a better outcome for a shorter duration of overall treatment time, especially for rapidly cycling tumor cells, i.e., having a small T,,, (8, 12, 13, 55, 56) . The feasibility of postoperative hyperfractionated accelerated radiotherapy (postop-HART; 48 Gy in 3 weeks) has recently been published (8). However, the median delay between surgery and initiation of adjuvant postop-HART was considered to be long, especially if fast-cycling cells were left after surgery.
In head and neck cancer and breast cancer, it has been shown that delaying the onset of adjuvant radiation might have a deleterious effect on local control and, hence, survival (6, 52) . This is thought to be due to induction of proliferative activity of residual clonogenic cells after resection of the tumor bulk (52) . This induction of proliferation of residual tumor cells might be linked to the appearance of growth factors, which is known to occur as a basic physiological mechanism in the wound-healing process.
The long delay between the two treatment modalities in trial 89-01 and the feasability of preoperative lowdose HART (trial 89-02; 32 Gy in 2 weeks for patients considered unresectable at presentation) formed the basis for the initiation of trial 91-01. In this latter Phase I trial, the preoperative dose was increased to 41.6 Gy in 2.5 weeks followed immediately by surgery. Patients with T3-T4 any N rectal cancer were eligible for this Phase I trial. We report the feasability of trial 9 l-01 and explain the different reasons favoring preoperative HART as compared to postoperative HART in T3-T4 any N rectal cancer.
METHODS

AND MATERIALS
In trial 89-01, a total dose of 48 Gy was applied postoperatively in 3 weeks. Patients not eligible for 89-01, because they were deemed unresectable at presentation, were included in 89-02 (32 Gy in 2 weeks followed rapidly by surgery). Since 1991, patients with Stage cT3-T4 (c = clinically staged as opposed to pathologic staging) any N rectal cancer were systematically introduced in trial 91-01 (41.6 Gy in 2.5 weeks followed by surgery within 6 days).
Prior to the initiation of the treatment, all patients underwent a complete clinical examination, blood count, assessment of renal and hepatic function, and CEA dosage. Distant metastatic disease was excluded by chest xray and abdominal ultrasound or computed tomography (CT scan). For patients enrolled in the preoperative HART trials, the assessment of the local extent of the tumor was done by digital examination, completed by rectal ultrasound and/or CT scan.
All patients were irradiated at the department of Radiation Oncology at CHUV with a linear accelerator with a minimal accelerating potential of 6 MV (clinac 2100 or linac 75-5). The dose per fraction was 1.6 Gy, and the interfraction interval was at least 6 h. The dose prescription was at the intersection of the fields (box technique). The homogeneity was within 5% of the dose prescribed at the isocenter.
The field margins were defined according to a "standard field," as described by Gunderson (18) . The upper limit was located at the L5-S 1 interspace. The lower limit was decided in function of the localization of the primary tumor. For low-located tumors, i.e., within a range of 5 cm from the anal margin, this latter was included in the treatment volume. For lesions located higher than 5 cm, the exclusion of the anal margin was checked by in vivo dosimetry using TLDs. Corrections of the lower limit were done if required.
Acute toxicity was assessed at least once a week during treatment and coded according to the WHO scale for skin and bowel and according to the RTGG scale for bladder. The treatment was never interrupted for acute toxicity. We focused our attention on small bowel toxicity because this was the dose-limiting toxicity in postop-HART. The small bowel toxicity was calculated as a mean value over the whole treatment period. For preoperative and postoperative HART, a correction of this mean toxicity score was done if patient initially presented with transit symptoms, i.e., diarrhea. The mean increase rather than the absolute values were compared between both trials. Corrections were required for three patients in trial 89-01 and seven patients in trial 91-01.
The amount of small bowel was estimated prior to the initiation of radiation treatment at the simulation. On those simulation films, the total surface of small bowel, both in anterioposterior and lateral fields, was calculated by superimposing a 1 cm spread grid (taking into account the magnification factor) (14). Surfaces of small bowel were expressed as a percent of total surface of the field after a correction has been made for individually shaped small bowel blocks.
Quantitative data such as small bowel surface, duration of treatment delay, and mean toxicity scores were compared with a two-sided t-test. Differences were considered significant if a 0.05 p-value was reached.
RESULTS
The feasibility of postoperative HART (trial 89-01) has been recently published (8). The dose-limiting factor in this Phase I trial was small bowel toxicity.
Trial 89-02 was characterized by a "negative" selec- (Table 1 ). All received 32 Gy in 2 weeks followed by surgery. Acute toxicity was minor and there were no treatment interruptions. Five patients underwent abdominoperineal resection and four, a low anterior resection (Table 2 ). All patients underwent a complete resection except one. The feasibility of preoperative low-dose HART in locally advanced rectal cancer and the high resectability ratio has served as the basis for conducting trial 91-01. In this latter trial, the preoperative dose has been raised to 41.6 Gy, and surgeons were asked to keep the interval between preoperative HART and surgery as short as possible, preferentially within 6 days. The patient characteristics of trial 89-01 and 91-01 are summarized in Table 3 . The age distribution was comparable. However, the tumor was more often located close to the anal margin in the preoperative trial (median distance 3 cm as compared to 6 cm). Nevertheless, the acute toxicity in trial 9 1-O 1 was acceptable. There was no report of acute small bowel toxicity exceeding Grade 2 WHO. There were no treatment interruptions. The mean corrected small bowel toxicity in trial 91-01 was significantly lower compared to trial 89-01 (p = 0.02) ( Table 4 ). This reduction of acute small bowel toxicity can be explained both by the lower total dose in trial 9 l-01 and by the significantly smaller amount of small bowel within the irradiation fields. The respective median values of small bowel, expressed in percent of the surface of the irradiation field, were 26% (range O-46%) for lateral fields and 10% (range O-21%) for anterior fields in trial 89-01, compared to, respectively, 0% (range O-12%) and 6% (range O-29%) in trial 91-01. Those differences are statistically significant (p < 0.001).
The timing between both treatment modalities was also significantly different (Table 5 ). The median delay between surgery and postoperative HART in 89-01 is 46 days (mean value 55), whereas in 91-01, this delay was 4 days (mean value 6 days) (p < 0.001). The duration of hospitalization after surgery has been compared. The preoperative approach could be at the origin of an increased perioperative morbidity. If this would be the case, we should expect an increased hospital stay for postoperative complications directly related to the preoperative treatment. Although there was a trend towards a prolonged hospital stay in trial 91-01 (29 vs. 26 days; p = 0. l), the median value of hospitalization duration in 91-01 was shorter than in trial 89-01 (respective median values: 19 vs. 21 days). The postoperative morbidity in 91-01 was characterized by wound-healing delay in three patients with abdominoperineal resection and one abscess formation after a low anterior resection. Although most of the patients presented with T4 rectal cancer in the 89-02 and 91-01 trial, all except one single patient were submitted to surgical resection of the tumor. This single patient presented initially with a very advanced rectal cancer infiltrating the sacral bone, the gluteal mass with fistulization at the skin. This patient was submitted to preoperative HART (41.6 Gy) and readressed to the surgeon, who decided that this tumor was definitely unresectable. Radiation therapy was immediately continued (twice-a-day 1.6 Gy with a field-size reduction) until the cumulative dose of 64 Gy was reached. This patient tolerated this high dose accelerated local treatment well and remains alive in partial remission, more than 1 year after treatment. The remaining 31 patients (trials 89-01 and 9 1-O 1) were submitted to a surgical procedure (2 1 abdominoperineal and 10 low anterior resections). Twenty-nine out of 31 patients underwent a curative resection (Table  2) . This latter was defined as surgery resulting in a negative proximal, distal, and radial margin.
Until now there is only one report of long-term toxicity, i.e., occurring at more than 6 months after completion of radiotherapeutic treatment, in patients treated in trial 89-01. This single patient had a bladder necrosis likely to be due in part to the aggressiveness of the initial surgical (A.M. = anal margin; FU = follow-up; Hosp = hospitalization; RT = radiotherapy).
procedure with nearly complete devascularization of this organ for oncological reasons. In trial 89-01, the median follow-up reaches 34 months. Thirteen out of 20 patients are alive with no evidence of disease. Three patients died of local progression and five of distant metastases (one patient with local progression had simultaneously distant metastases). However, in two out of these three, local recurrences were found in patients treated by postoperative HART after salvage surgery for a recurrence. The median follow-up in trial 91-01 reaches 19 months. There was only one report of a late complication in this Phase I trial (grade 3 small bowel toxicity).
The pathologic staging (pT) has been compared with the clinical staging (CT) in trial 91-01 (Fig. 1) . The clinical staging, i.e., digital examination completed by rectal ultrasound or CT-scan, seems to be suboptimal. There is a frequent mismatch between preoperative assessment of T-stage and pathologic assessment of infiltration (Fig. 1) . It cannot be excluded, however, that there is a downstaging on the tumor even after a short delay between preoperative irradiation and surgery. For N-staging, both rectal ultrasound and CT-scan seem to be unreliable for assessment of nodal involvement prior to the treatment.
In summary, the results for both modalities (postoperative HART 48 Gy vs. preoperative HART 41.6 Gy) are illustrated in Table 6 and Table 7 .
DISCUSSION
Both local recurrence and distant metastases after surgery remain a major problem in the curative approach of rectal cancer. Adjuvant radiation therapy can reduce the incidence of local recurrence and, therefore, this treatment modality is currently considered as a part of the standard treatment (33) . This adjuvant radiation treatment can be given pre-, post-, or intraoperatively (17, 34, 39, 46, 47 (Dur. RT = duration of radiation treatment, Hosp = hospitalization stay after surgery and delay between radiotherapy and surgery -delay RT/S -are expressed in days).
Although the treatment was feasible as far as acute toxicity was concerned, the rather long delay between surgery and the inititiation of the adjuvant accelerated hyperfractionated radiotherapy was a matter of concern, especially since rectal cancer is characterized by fast cellular kinetics (36, 48) . Recently published values for potential doubling time (T,,,), assessed by Iodo-deoxy-uridine (Iudr) injection and flow cytometric measurement of labeling index and Ts, seem to confirm our concern (3, 36,48, 54). The published T,, values in rectal cancer are even shorter than those measured in head and neck cancer (54) . Finally, the dose-limiting small bowel toxicity observed in trial 89-01 (postoperative 48 Gy in 3 weeks), prohibits any further increase in the intensity of the treatment by, for example, combination with chemotherapy (8).
The feasibility of "low-dose" (32 Gy in 2 weeks) hyperfractionated accelerated radiotherapy in ' 'unresectable" rectal cancer (trial 89-02), and the high resectability ratio obtained in this small series, served as the basis for initiation of a "moderate dose" preoperative Phase I trial. The dose increment between trial 89-02 and trial 91-9 1 was in accordance to the dose response data obtained by an extensive review of the literature (15, 20, 21, 32, 35, 37, 40, 42) . Low-dose radiotherapy has no significant effect on local control (20, 32, 37, 40) , whereas doses higher than 20 Gy seem to significantly affect local recurrence rate (15, 42) . It is interesting to note that both in the Stockholm Trial and in the EORTC 40761 trial there is a positive impact of radiation on pelvic control. These latter trial are characterized by a "short" delay (< 2 weeks) between both treatment modalities (15, 42). Therefore, we assume that in other trials, especially the VASAG II and the EORTC 40741 trials, the prolongation of the interval might have cancelled the effect of the preoperative treatment at a dose level where one should await an impact on local control (4, 21). Attempts to modify the intensity and, hence, the efficacy of preoperative radiotherapy are currently under investigation (5, 11, 19, 25-28, 30, 31, 47, 50, 53) . The enhancement of the therapeutic effect might be obtained by accelerating the treatment or adding chemotherapy. Again, the overall treament time might be important in this particular choice. To keep the total treatment duration of the local combined approach (i.e., radiotherapy and surgery) as short as possible, we decided to accelerate the treatment preoperatively and reduce the interval between both modalities. The median interval in the present series is only 4 days. Some authors involved in the search of optimized preoperative radiation treatment argue that the delay between radiotherapy and surgery is beneficial especially for tumor shrinkage and reduction of local inflammatory postradiation reaction. This tumor shrinkage is illustrated by reports of high resectability ratio (5, 19, 22, 23, 25-28, 30, 31, 50) . However, comparison of resectability ratios is hampered by variations in preoperative staging and definition of locally advanced or marginally resectable rectal cancer. Most of our patients presented initially with T3-T4 in any N rectal cancer and a large proportion of those patients (29 out of 32) underwent a "curative resection" (= negative margin inclusive radial margins), although the median interval between both treatment modalities was only 4 days.
Any increase of the radiation-related surgical morbidity would preclude further exploitation of the potential benefit of the reduction of the overall treatment time. In our hands, the hospitalization duration after surgery was not increased as compared to our initial postoperative series. The feasibility of this new approach by other centers has Interval RT/S = delay between RT (radiotherapy) and surgery (S), expressed in days; %SB = small bowel surface in percent of field surface corrected (c) for individual blocking, respectively, for anteroposterior fields (AP) and lateral fields (Lat); HART = hyperfractionated accelerated radiotherapy.
yet to be defined and a larger Phase II trial is currently ongoing. Preoperative chemotherapy may not be needed 1.
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in conjunction with preoperative accelerated radiotherapy to get the best local effect, but it is probably required for its systemic effect. However, to keep overall treatment time for local control as short as possible, we aim at adding chemotherapy as an adjuvant immediately after surgery. However, the final impact of preoperative accelerated radiotherapy should be compared to a "standard" treatment emerging from currently ongoing trials within the frame of a randomized multicentric trial.
CONCLUSIONS
Our initial experience of accelerating radiotherapy in a postoperative setup and the feasibility of low-dose preoperative acceleration in locally advanced rectal cancer formed the basis of the moderate dose preoperative acceleration in rectal cancer rapidly followed by surgery. The lack of a significant toxicity, the high resection rate, the short interval between radiation and surgery, and the reduction of small bowel volume as compared to postoperative irradiation have been used as rationales to start a multicentric Phase II study.
